Pursuant to Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, please find attached the Unaudited Standalone and Consolidated Financial Results of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries reported strong Q3 FY26 results. Standalone revenue from operations rose about 37% year-on-year to roughly Rs.158.37 crore, up from Rs.115.58 crore in Q3 FY25. Standalone net profit climbed about 56% to Rs.4.31 crore versus Rs.2.76 crore a year ago. For the nine-month period, standalone revenue grew 37% to Rs.467.69 crore and net profit jumped about 78% to Rs.12.43 crore. Basic EPS for 9M FY26 stood at Rs.0.52 compared with Rs.0.29 in 9M FY25. The board also cleared setting up a new wholly-owned subsidiary in Poland, signed a deal to buy an API manufacturing facility in Telangana for Rs.25.50 crore, and received BSE in-principle approval to issue Foreign Currency Convertible Bonds worth up to USD 35 million (out of a Rs.1,500 crore authorisation). The statutory auditor, NGST & Associates, issued an unmodified limited review opinion, and the company voluntarily adopted Ind AS for the first time with a transition date of April 1, 2024, leading to restatement of prior period figures.
Sharp revenue and profit growth along with a new overseas subsidiary and acquisition signal business momentum, which is positive for shareholders. The proposed FCCB issue, if eventually launched, could dilute equity, so investors should watch for further announcements on size, pricing, and timing.